162 related articles for article (PubMed ID: 35122394)
21. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
[TBL] [Abstract][Full Text] [Related]
22. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
23. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
24. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
Martin DJ; Ramirez-Alvarado M
Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
[TBL] [Abstract][Full Text] [Related]
25. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
27. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
[TBL] [Abstract][Full Text] [Related]
28. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
29. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J
J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870
[TBL] [Abstract][Full Text] [Related]
30. Altered dimer interface decreases stability in an amyloidogenic protein.
Baden EM; Owen BA; Peterson FC; Volkman BF; Ramirez-Alvarado M; Thompson JR
J Biol Chem; 2008 Jun; 283(23):15853-60. PubMed ID: 18400753
[TBL] [Abstract][Full Text] [Related]
31. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
32. Future directions in the clinical management of amyloid light-chain amyloidosis.
Haider S; Ahmad N; Anaissie E; Driscoll JJ
Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
[TBL] [Abstract][Full Text] [Related]
33. Towards understanding the structure-function relationship of human amyloid disease.
Dealwis C; Wall J
Curr Drug Targets; 2004 Feb; 5(2):159-71. PubMed ID: 15011949
[TBL] [Abstract][Full Text] [Related]
34. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
35. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
36. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
38. Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue.
Baur J; Berghaus N; Schreiner S; Hegenbart U; Schönland SO; Wiese S; Huhn S; Haupt C
Amyloid; 2023 Mar; 30(1):27-37. PubMed ID: 35792725
[TBL] [Abstract][Full Text] [Related]
39. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
40. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
